Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Deletion of the multidrug resistance protein 1 (MRP1) gene in acute myeloid leukemia patients with inversion 16: expression of MRP1 homologues

Leukemia volume 15, pages 191–192 (2001)Cite this article

In the prospective study of Döhner et al,1 it is described that the deletion of the multidrug resistance protein (MRP1) gene has no prognostic impact in acute myeloid leukemia (AML) patients with an inversion on chromosome 16. These findings are in agreement with the results we recently described,2 and might be due to the fact that the expression of MRP1 homologues can be upregulated in the case of MRP1 deletion.

MRP1, encoded by the MRP1 gene located on chromosome 16p13, is a member of the superfamily of ATP-binding cassette (ABC) transporters. MRP1 has been shown to transport a broad range of organic substrates, and the expression of MRP1 results in resistance to different classes of chemotherapeutic agents. The MRP family of proteins consists of at least six family members, MRP1 to MRP6.3 However, the role of the MRP1 isoforms is not yet well defined. MRP2, MRP3 and MRP5 have been described to transport chemotherapeutic agents, such as cisplatin, doxorubicin, etoposide and 6-mercaptopurine, but less is known about the transport mechanisms of the proteins MRP4 and MRP6. Another membrane transporter, P-glycoprotein (P-gp) encoded by the MDR1 gene, has also been shown to transport chemotherapeutic drugs. The simultaneous expression and function of both proteins has been shown to be correlated with poor overall survival in AML.4

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Döhner K, Schlenk RF, van der Reijden BA, Döhner H . Deletion of the multidrug resistance-associated protein (MRP1) gene in acute myeloid leukemia with inversion of chromosome 16 has no prognostic impact Leukemia 2000 14: 1154

    Article  PubMed  Google Scholar 

  2. Van der Kolk DM, Vellenga E, van der Veen AY, Noordhoek L, Timmer-Bosscha H, Ossenkoppele GJ, Raymakers RA, Müller M, van den Berg E, de Vries EGE . Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity Blood 2000 95: 3514–3519

    CAS  PubMed  Google Scholar 

  3. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk M, Juijn JA, Baas F, Borst P . Analysis of expression of cMOAT (MRP2), MRP3, MRP4 and MRP5, homologs of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines Cancer Res 1997 57: 3537–3547

    CAS  PubMed  Google Scholar 

  4. Van der Kolk DM, de Vries EGE, van Putten WLJ, Verdonck LF, Ossenkoppele GJ, Verhoef GEG, Vellenga E . P-gp and MRP activities in relation to treatment outcome in acute myeloid leukemia Clin Cancer Res 2000 6: 3205–3214

    CAS  PubMed  Google Scholar 

  5. Kuss BJ, Deeley RG, Cole SPC, Willman CL, Kopecky KJ, Wolman SR, Eyre HJ, Lane SA, Nancarrow JK, Whitmore SA, Callen DF . Deletion of gene for multidrug resistance in acute myeloidleukaemia with inversion in chromosome 16: prognosticimplications Lancet 1994 343: 1531–1534

    Article  CAS  PubMed  Google Scholar 

  6. Van der Kolk DM, de Vries EGE, Koning JA, van den Berg E, Müller M, Vellenga E . Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells Clin Cancer Res 1998 4: 1727–1736

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Haematology, University Hospital of Groningen, Groningen, The Netherlands

    DM van der Kolk & E Vellenga

  2. Division of Medical Oncology, University Hospital of Groningen, Groningen, The Netherlands

    DM van der Kolk & EGE de Vries

Authors
  1. DM van der Kolk
    View author publications

    Search author on:PubMed Google Scholar

  2. EGE de Vries
    View author publications

    Search author on:PubMed Google Scholar

  3. E Vellenga
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

van der Kolk, D., de Vries, E. & Vellenga, E. Deletion of the multidrug resistance protein 1 (MRP1) gene in acute myeloid leukemia patients with inversion 16: expression of MRP1 homologues. Leukemia 15, 191–192 (2001). https://doi.org/10.1038/sj.leu.2401949

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.leu.2401949

Search

Advanced search

Quick links